This checker was developed for the Australian veteran population and may not be universally applicable. This page was last updated on 09/08/2022.
The suggested actions and clinical comments are based on available information sources including the Australian Product Information, available at the Australian Register of Therapeutic Goods Website, the Liverpool COVID-19 Interactions Checker, the Ontario COVID-19 Science Advisory Table and the NIH Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid®) and the Concomitant Medication . For some medicines, data on nirmatrelvir plus ritonavir interaction is limited.
Contraindicated (Red) - For these medicines, there is a risk of serious side effects or reduced treatment efficacy. Do not co-administer with nirmatrelvir plus ritonavir.
Attention required (Orange) - There is potential interaction with nirmatrelvir plus ritonavir, and clinical evaluation of current therapy is recommended.
Follow up (Grey) - The potential interaction usually does not require pre-emptive therapy change, but should be monitored over time.
No known interaction (Green) - No interaction between this medicine and nirmatrelvir plus ritonavir is expected.